Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840772 | 0.90 | LMNA (0.40) | LMNASMN1; SMN2PABPC1ATMKMT2A | |
| SCHEMBL985894 | 0.72 | NOS3 (0.44) | LMNASMN1; SMN2PABPC1ATMKMT2A | |
| SCHEMBL2835727 | 0.71 | L3MBTL1 (0.42) | LMNASMN1; SMN2PABPC1ATMKMT2A | |
| SCHEMBL2835764 | 0.70 | GAA (0.40) | LMNASMN1; SMN2ATMKMT2AL3MBTL1 | |
| SCHEMBL568818 | 0.70 | TSHR (0.47) | LMNASMN1; SMN2PABPC1ATMKMT2A | |
| SCHEMBL11072823 | 0.69 | TSHR (0.55) | LMNASMN1; SMN2KMT2AL3MBTL1TDP1 | |
| SCHEMBL11071015 | 0.69 | ALDH1A1 (0.45) | LMNASMN1; SMN2PABPC1ATMKMT2A | |
| SCHEMBL8187218 | 0.69 | MEN1 (0.41) | LMNASMN1; SMN2PABPC1ATMKMT2A | |
| SCHEMBL2840999 | 0.69 | KMT2A (0.43) | LMNASMN1; SMN2KMT2AL3MBTL1TDP1 | |
| SCHEMBL21767046 | 0.69 | LMNA (0.43) | LMNASMN1; SMN2PABPC1ATMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217031-B2 | Heteroaryl derivatives | NIPPON SHINYAKU CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100048537-A1 | HETEROARYL DERIVATIVES | NIPPON SHINYAKU CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2141168-A1 | HETEROARYL DERIVATIVES | Nippon Shinyaku Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048537-A1 | HETEROARYL DERIVATIVES | OPRD1, OPRM1, OPRK1 | LMNA 4746/4885SMN1; SMN2 723/4885PABPC1 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.